Showing 1461-1470 of 5827 results for "".
Cutaneous Oncology Update: Dr. Ruiz
https://practicaldermatology.com/programs/practical-dermatology/cutaneous-oncology-update-dr-ruiz/32696/Emily Ruiz, MD, discusses the key points she covered about nonmelanoma skin cancer during "Cutaneous Oncology Update 2025" at Maui Derm 2025, as well as her poster presentation on the 40-GEP test for head and neck cutaneous squamous cell carcinomas.Neuromodulators and Dermal Fillers: Dr. Gold
https://practicaldermatology.com/programs/practical-dermatology/neuromodulators-and-dermal-fillers-dr-gold/32694/Michael Gold, MD, talks about the new neurotoxins and applications, as well as fillers, that he covered during "Neuromodulators and Dermal Fillers: What's New, What's Coming and What Are We Doing That's New in 2025" at Maui Derm 2025.Combination Treatment: Dr. Shamban
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/combination-treatment-dr-shamban/32685/Ava Shamban, MD, talks about the combination treatments—such as energy-based devices, peels, and laser-assisted drug delivery—that she covered in "What's My Treatment? How to Combine Dermal Filler, Neuromodulators, Laser/Light/RF Devices/Microneedling and Cosmeceuticals Symposium" at Maui Derm 2025."You've Just Been Served": Dr. Goldberg
https://practicaldermatology.com/programs/practical-dermatology/youve-just-been-served-dr-goldberg/32691/David Goldberg, MD, JD, discusses lessening the likelihood of lawsuits and winning lawsuits involving negligence, employees, and teledermatology, which he covered during his session, "You've Just Been Served," at Maui Derm 2025.Clinical Development of Emrosi for Rosacea
https://practicaldermatology.com/series/c-suite-chats/clinical-development-emrosi-rosacea/32379/Claude Maraoui, President and CEO of Journey Medical, discusses the clinical development program for Emrosi, which was recently approved by the FDA for inflammatory lesions of rosacea in adults.Improving Treatment Capabilities for Vitiligo
https://practicaldermatology.com/series/c-suite-chats/improving-treatment-capabilities-for-vitiligo/29745/David Domzalski, CEO and President of Vyne Therapeutics, discusses what makes vitiligo difficult to treat and how his company is working to address those challenges.Dermatology Innovations
https://practicaldermatology.com/topics/psoriasis/dermatology-innovations/20044/From topical therapies to JAK inhibitors, there are many new drugs available to treat a wide variety of dermatologic conditions. Neal Bhatia, MD reviews what's new for atopic dermatitis, alopecia areata, scabies, lice, onychomycosis, and more. Plus, he discusses the importance of new delivery systemConversations in Acne, Part 3
https://practicaldermatology.com/topics/acne-rosacea/conversations-in-acne-part-3/19877/What do we know about the anti-inflammatory effects of antibiotics? How can we reduce risks for creating resistance or affecting the gut microbiome? Host Neal Bhatia, MD leads a conversation on these topics and more with Hilary Baldwin, MD and James Q. Del Rosso, DO.Is There Evidence that Topical Formulations Can Support the Microbiome?
https://practicaldermatology.com/topics/atopic-dermatitis/is-there-evidence-that-topical-formulations-can-support-the-microbiome/19826/There is a growing body of research on the importance of the microbiome as well as the potential to support a healthy microbiome through topical product selection, Dr. Friedman says.Actinic Keratosis: Therapy Overview
https://practicaldermatology.com/topics/skin-cancer-photoprotection/actinic-keratosis-therapy-overview/19732/Joel Cohen, MD interviews George Martin, MD about the latest developments in actinic keratosis. Dr. Martin said he is eagerly awaiting regulatory review of tirbanibulin, which showed promising results in clinical trials. The two also discuss practical tips and nuances of using 5FU in practice. *Be s